key: cord-0769706-c6c63mfs
authors: Peghin, Maddalena; De Martino, Maria; Palese, Alvisa; Gerussi, Valentina; Bontempo, Giulia; Graziano, Elena; Visintini, Erica; Elia, Denise D’; Dellai, Fabiana; Marrella, Francesco; Fabris, Martina; Curcio, Francesco; Sartor, Assunta; Isola, Miriam; Tascini, Carlo
title: Post-COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients
date: 2022-03-23
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.03.016
sha: ef988fd8dfdd7ffdb737e3a0f8819b755d394ed4
doc_id: 769706
cord_uid: c6c63mfs

OBJECTIVES: To describe the impact of vaccination and the role of humoral responses on post-coronavirus disease 2019 (COVID-19) syndrome one year after the onset of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: A prospective study. Interviews investigated post-COVID-19 syndrome 6 and 12 months after the disease onset of all adult in- and outpatients with COVID-19 attending Udine Hospital (March–May 2020). Vaccination status and two different serological assays to distinguish between response to vaccination (receptor-binding domain –RBD SARS-CoV-2 IgG) and/or natural infection (non-RBD- SARS-CoV-2 IgG) were also assessed. RESULTS: 479 individuals (52.6% female, mean age 53 years) were interviewed 13.5 months (0.6 SD) after acute infection. Post-COVID-19 syndrome was observed in 47.2% (226/479) of patients after one year. There were no significant differences in the worsening of post-COVID 19 symptoms (22.7% vs 15.8%, p = 0.209) among vaccinated (n=132) and unvaccinated (n=347) patients. The presence of non-RBD SARS-CoV-2 IgG induced by natural infection showed a significant association with post-COVID-19 syndrome (OR 1.35, 95% CI 1.11–1.64, p = 0.003), and median non-RBD SARS-CoV-2 IgG titres were significantly higher in long-haulers than in patients without symptoms 22 (IQR 9.7–37.2) vs 14.1 (IQR 5.4–31.3) kAU/L, p = 0.009) after one year. In contrast, the presence of RBD SARS-CoV-2 IgG was not associated with the occurrence of post-COVID-19 syndrome (>2500 U/mL vs 0.9–2500 U/mL, OR 1.36, 95% CI 0.62–3.00, p = 0.441) and RBD SARS-CoV-2 IgG titres were similar in long-haulers than in patients without symptoms (50% values > 2500 U/mL vs 55.6% values > 2500 U/mL, p = 0.451) CONCLUSIONS: The SARS-CoV-2 vaccination is not associated with the emergence of post-COVID-19 symptoms over one year after acute infection. The persistence of high serological titres response induced by natural infection but not by vaccination, may play a role in long-COVID-19.

Post-coronavirus disease 2019 (COVID- 19) syndrome is a heterogeneous, multisystemic, post-acute sequelae impacting health and the quality of life of all ages (1) (2) (3) . The potential pathophysiological mechanisms are unknown and may encompass a complex interaction between the virus-specific cytopathic effects, the inflammatory damage, the allo-and autoimmune responses to the acute infection on the one hand, and the expected sequelae of post-critical illness due to organ and microvascular damage on the other (4). To date, there is still a gap on how natural immunity and hybrid immunity, which refer to the immune-strengthening effect of exposure to infection followed by vaccination, function in post-COVID 19 (5) (6) (7) . A few studies available have suggested both a potential improvement and deterioration of post-COVID-19 symptoms after vaccination in previously infected patients and variable associations between humoral responses and post-COVID-19 syndrome after the natural infection (8) (9) (10) (11) . Investigating immunological mechanisms could inform both clinical and public health decisions regarding the prevention of and the potential tailored treatments for long COVID-19 (4). Thus, the aim of this study was to describe the post-COVID-19 syndrome one year after the acute infection by focusing (a) on the influence of vaccination on long-term symptoms, and (b) on the role of humoral responses among survivors with natural and hybrid immunity.

A prospective study (5) reported according to the Strengthening the Reporting of Observational Studies in Epidemiology Statement (Supplementary Table 1 ). Those eligible were: (a) all adults (≥ 18 years) diagnosed with COVID-19 during the first wave (March-May 2020) and cared for by an Academic Hospital in all settings (b) followed up at 6 (September-November 2020) and at 12 months (March-May 2021); and (c) willing to participate ( Figure 1 ).

Demographic and clinical databases were populated at the enrolment and over time (Supplementary Table 2 ).

Participants were telephone-interviewed by the same trained nurses at 6 and 12 months using a homogeneous questionnaire, pilot-tested and previously validated (5), investigating persistent or emerging symptoms potentially associated with COVID-19, as expressed by patients' own words (12). Post-COVID-19 syndrome was defined as signs and symptoms developed during or following an infection consistent with COVID-19, continued for more than 12 weeks, and not explained by an alternative diagnosis (13). Signs/symptoms reported by patients were classified by four J o u r n a l P r e -p r o o f 4 independent researchers (Supplementary Table 3 ) and then matched between the first and the second interview in order to check changes, if any, over time. Therefore, patients were classified as: (a) unaffected when asymptomatic at both follow-ups; (b) unchanged when symptoms remained the same; (c) worsened when new symptoms emerged; and (d) improved, when symptoms were recovered/resolved (5) .

In Italy, the SARS-CoV-2 vaccination campaign started on 27 December 2020. Vaccines approved were those with Adenovirus Vector (ChAdOx1 nCoV-19 Oxford-AstraZeneca and Ad26.COV2.S Janssen COVID-19 vaccine) and the mRNA (BNT162b2 Pfizer-BioNTech and mRNA-1273 Moderna). Thus, at 12 months, patients were asked to communicate vaccination state (yes/no) by also reporting the date and type of vaccine received. Data collected were matched in their accuracy with electronic health records; then, patients were categorized as vaccinated if they had received the vaccine at least 2 weeks before the interview; those with combined immunity from natural SARS-CoV-2 infection and vaccination were considered to have hybrid immunity. Bias has been prevented, as reported in Supplementary Table 4 .

SARS-CoV-2 antibody measurement were performed in a subgroup of patients (n=546) who agreed to participate in a parallel study (CORMOR 3-4®) (14) : their serological data at the time of the interview (+/-2 months) were recorded in the database (Figure 1 ). The role of serological response in post-COVID-19 syndrome was assessed by using two antibody assays with different abilities to recognize the receptor-binding domain (RBD) of the Spike protein as the main target stimulated by the SARS-CoV-2 vaccination. Specifically, an IgG test that is not able to recognize the RBD SARS-CoV-2 protein (iFlash-SARS-CoV-2; IgG positivity cut-off > 10.0 kAU/L) was used to follow natural humoral response (non-RBD IgG) and an IgG test of the SARS-CoV-2 S protein RBD (Elecsys Roche; IgG positivity cut-off (< 0.9 U/mL and maximum value > 2500 U/mL ) was used to follow both natural and vaccine-induced humoral response to compare vaccinated and unvaccinated patients ( Figure 1 ). Laboratory methods used are detailed in Supplementary Table 5 .

The reference Ethics Committee of Friuli Venezia Giulia (CEUR-2020-OS-219 and CEUR-2020-OS-205) approved the study.

J o u r n a l P r e -p r o o f 5

Patients were divided into two groups (vaccinated, unvaccinated) at the time of the interview at 12 months. The Shapiro-Wilk test was used to assess whether data were normally or non-normally distributed. Categorical variables were compared using the chi-square (χ2) test or Fisher's exact test, while quantitative variables were compared using the t-test or Mann-Whitney U test, as appropriate. A univariable and multivariable logistic regression was performed to explore features associated with post-COVID-19 syndrome, estimating the odds ratio (OR) at 95% Confidence Interval (CI), (STATA 17.0).

Overall, during the first wave, 1,067 COVID-19 patients were diagnosed in our hospital. Of them, 599 attended the 6month interview and 479 the 12-month interview ( Figure 1 ). Their baseline characteristics and clinical data at the COVID-19 onset are reported in Table 1 Specifically, there was a significant increase in rheumatological (6.3% vs 12.7%, p = 0.002), ocular (0.3% vs 23%, p < 0.001) and psychiatric symptoms (4.8% vs 10.2%, p = 0.006), whereas there was a significant decrease in neurological (9.5% vs 2.7%, p < 0.001) and cutaneous symptoms (3.5% vs 1.2%, p = 0.047) at 12 months compared with 6 months ( Figure 2 ). Tables 1 and 2 , vaccinated patients were more frequently female (94/132, 71.2%) and health-care workers (HCWs) (73/120, 60.8%), with a less severe disease at acute onset (105/132, 79.5% mild or asymptomatic). In both groups, there were patients still suffering from post-COVID-19 symptoms at 6 months, but those unvaccinated had reported higher rates of symptoms at 6 months compared to those who were vaccinated (45.2% vs 33.3%, p = 0.018). Table 3 , post-COVID-19 symptoms varied between 6 and 12 , according to the vaccination status: in both groups, there were patients whose symptoms had worsened (22.7% vs 15.8%) or improved (11.4% vs 13.0%), although most commonly, patients reported unchanged symptoms or to be unaffected (65.9% vs 71.2%).Overall, these differences were not statistically significant except for the improvement in hair loss among unvaccinated (p = 0.033) and the worsening ocular symptoms among those vaccinated patients (p = 0.021). No significant difference in post-COVID-19 syndrome at 12 months emerged according to the vaccine received (45.8% mRNA vaccine and 12.5%

Adenovirus Vector vaccine, p = 0.137) and the vaccination status (38.1% incomplete and 45.9% complete, p=0.507).

Multivariable analyses of post-COVID-19 syndrome risk factors associated are reported in Supplementary tables 6 and 7.

Patients included in the CORMOR 3-4 study were monitored ( Table 4 ).

In contrast, the presence of RBD SARS-CoV-2 IgG in patients with hybrid immunity compared with those with natural immunity was not linked with the development of post-COVID-19 syndrome (> 2500 U/mL vs 0.9-2500 U/mL, OR 1.36, 95% CI 0.62-3.00, p = 0.441) and RBD SARS-CoV-2 IgG titres were similar in long-haulers and in patients without symptoms (50% values > 2500 U/mL vs 55.6% values > 2500 U/mL, p = 0.451). The antibody response among vaccinated and unvaccinated patients is shown in Table 4 . (2, 17) . Numerous multisystem symptoms were reported, although rheumatological, anosmia/dysgeusia, fatigue, dyspnoea and psychiatric disorders were the most common (2, 18) . Interestingly, at 12 months we found a significant increase in rheumatological, psychiatric and ocular symptoms compared with those reported at 6 months; in contrast, there was a significant decrease in neurological symptoms (3, 18) . This delayed increase in rheumatological symptoms may confirm the role of persistent immunemediated mechanisms, confirming the potential of SARS-CoV-2 to trigger autoimmune manifestations (2, 4). Mental health issues have been reported more frequently than in those recovering from other infectious diseases, possibly due to the traumatic effects of the COVID-19 pandemic on mental health (16, 19) .

The potential immune-mediated hypotheses of long COVID-19 remains uncertain (7, 20) . Vaccination against SARS-CoV-2 is a leading strategy to change the course of the COVID-19 pandemic worldwide, reducing the risk of infection, that of severe complications and the long-term effects in the case of a breakthrough infection (8, 9, 21) . Moreover, vaccines have shown to increase immunogenicity, antibody titres, and reactogenicity in individuals with past infection compared with naive patients (22) . Vaccine hesitancy of previously infected patients and long-haulers might be due to the belief that, having developed a dysregulated response to natural infection, that may be exacerbated by vaccination, and also to the perception that protection is acquired with previous infection, as observed in our cohort (11, 23) .

However, a limited evidence with conflicting results is available on the potential impact of vaccination on post-COVID-19 symptoms (7, 10, 11). Our findings suggest vaccination is not associated with worsened symptoms as when comparing vaccinated and unvaccinated patients, symptoms were mostly improved or unchanged. Of interest, we only found an improvement in hair loss and worsening of ocular symptoms among unvaccinated patients. Telogen effluvium J o u r n a l P r e -p r o o f 8 is a disorder induced by a wide variety of endogenous and exogenous factors, including COVID-19 infection (2) . Ocular morbidities in long-haulers are an emerging problem that needs to be further studied (24) .

Knowledge concerning humoral immune response to SARS-CoV-2 and its relationship with post-COVID-19 syndrome is still incomplete (5, 6, 25-27). We found a significant association between growing titres of non-RBD SARS-CoV-2 antibodies after natural infection and post-COVID-19 syndrome in the prolonged follow-up. In contrast, the presence and persistence of RBD IgG stimulated by the vaccine in patients with hybrid immunity were not associated with post-COVID-19 compared with patients with natural infection. The immune response induced by vaccines is a highly targeted response to the Spike protein of the SARS-CoV-2 virus and may help the immune system to tackle the possible viral reservoir, reducing the chance of non-specific immune reactions and resetting the immune response (22, 26, 28, 29) . In contrast, the response triggered by natural infection is broader and may stimulate an excessive or dysregulated alloand autoimmune response and uncontrolled inflammatory activity (22, 30) . Based on our data on vaccination and humoral response, the SARS-CoV-2 vaccination should be recommended in patients with a history of previous COVID-19 because further vaccine immune stimulation may not exacerbate sequalae nor produce an altered humoral response.

Moreover, long-COVID-19 patients would benefit from vaccination to reduce their risk of further infection and to avoid the risk of a vicious immune circle (31, 32) . This study has several limitations. It has involved a single-centre study including patients cared for in the first wave, limiting its generalizability given that the emergence of SARS-CoV-2 variants of concern may affect the clinical presentations, the serological responses, the occurrence and the severity of long-COVID. Moreover, a 20% drop-off rate between the 6 and 12 month interviews was observed and only COVID-19 patients were included, thus lacking in a control group (16). Furthermore, given that vaccine programme in Italy prioritized HCWs and elderly patients this might have introduced a gender bias (23) . Symptoms were self-reported and subjectivity may have affected the findings.

Additionally, the test accuracy, positivity cut-offs and kinetics of antibodies may be assay-dependent, and measuring antibodies may be a limited indicator of immunity without the determination of cellular immunity. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease

Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy

Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients

The Association Between Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Post-COVID-19 Syndrome in Healthcare Workers

Are vaccines safe in patients with Long COVID? A prospective observational study

Breakthrough Symptomatic COVID-19 Infections Leading to Long Covid: Report from Long Covid Facebook Group Poll

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study

Do vaccines protect against long COVID? What the data say 2021

The Impact of COVID Vaccination on Symptoms of Long COVID. An International Survey of People with Lived Experience of Long COVID. 2021. 12. Powers JH, 3rd

The Fall in Antibody Response to SARS-CoV-2: a Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery

Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic

Twelve-month systemic consequences of COVID-19 in patients discharged from hospital: a prospective cohort study in Wuhan, China

Long-Term Effects of COVID-19

Postintensive Care Syndrome in Survivors of Critical Illness Related to Coronavirus Disease 2019: Cohort Study From a New York City Critical Care Recovery Clinic

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections

Immune Responses against SARS-CoV-2-Questions and Experiences

Vaccine Hesitancy among Italian Patients Recovered from COVID-19 Infection towards Influenza and Sars-Cov-2 Vaccination. Vaccines (Basel)

Ocular findings among patients surviving COVID-19

Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection

Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination

One-year sustained cellular and humoral immunities of COVID-19 convalescents

Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells

Testing for responses to the wrong SARS-CoV-2 antigen?

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination -Kentucky

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity -Nine States

Flow diagram of in-and out-COVID-19 patients included in the post-COVID-19 syndrome study at 6-12 months and serological follow-up up to

SARS CoV-2 vaccination campaign started on 27 December 2020 tested non-RBD SARS-CoV-2 IgG * and 102 patients tested RBD SARS-CoV-2 IgG concentrations at 12 months §

Severe Acute Respiratory Syndrome Coronavirus 2 Legend: CORMOR 3-4 study * non-RBD SARS-CoV-2 IgG antibodies (iFlash ® ) concentrations were measured at the serological follow-up visits each month (+/-15 days) after symptom onset during the first four months, and every month up to 12 months (+/-15 days

IgG antibodies (Roche ® ) at 12 months after the onset of symptom (+/-60 days). Patients were categorized as

The authors would like to thank all clinical and nursing staff who cared for the patients at Udine Infectious Disease Clinic during hospitalization and ambulatory management. The authors are grateful to all patients for their collaboration.